In this article, we will take a look at the 5 Best Large Cap Dividend Growth Stocks to Invest In. For deeper discussion and analysis, read 10 Best Large Cap Dividend Growth Stocks to Invest In.
5. Ecolab Inc. (NYSE:ECL)
Number of Hedge Fund Holders: 62
On April 29, Bank of America lowered its price recommendation on Ecolab Inc. (NYSE:ECL) to $335 from $345. It reiterated a Buy rating on the shares. The firm said it is cutting its 2026 and 2027 EPS forecasts to better reflect the expected dilution in the second half of 2026 from CoolIt, the analyst tells investors in a post-earnings note.
During its Q1 2026 earnings call, Ecolab CEO, President, and Chairman Christophe Beck said the quarter reflected strong performance, with momentum building across the portfolio. He noted that adjusted diluted EPS increased 13%, while organic sales rose 4%. Growth came from value pricing, which contributed 3%, along with volume growth that improved to 1%. Beck also said both the Global High-Tech and digital segments delivered growth of more than 20%. He added that the Life Sciences segment accelerated to 11% growth, supported by bioprocessing, where sales more than doubled.
Looking ahead, he said the company expects Life Sciences to maintain double-digit growth. He also noted that operating income margins in that segment are projected to expand toward a 30% target over the next few years.
Ecolab Inc. (NYSE:ECL) provides water, hygiene, and infection prevention solutions and services that protect people and critical resources. Its Global Industrial segment offers water treatment and process applications, along with cleaning and sanitizing solutions, primarily for large industrial customers.
4. McKesson Corporation (NYSE:MCK)
Number of Hedge Fund Holders: 72
On April 28, William Blair initiated coverage of McKesson Corporation (NYSE:MCK) with an Outperform rating. The company has a “durable competitive moat” with specialty-led growth upside, the analyst tells investors in a research note. The firm believes McKesson is well-positioned to benefit from a favorable demand backdrop, supported by demographic trends and rising use of specialty medicines.
On April 20, Reuters reported that McKesson will sell a minority stake in its medical-surgical solutions business to Apollo Global Management for $1.25 billion, as the company plans to spin off the unit through an initial public offering. Apollo will acquire about 13% of the business through a convertible preferred equity investment, valuing it at roughly $13 billion, while McKesson will retain control and majority ownership of the unit, the companies said.McKesson is streamlining its operations to focus on its core pharmaceutical distribution business after years of investor pressure.
The investment by Apollo is a crucial milestone that helps reduce uncertainty around the medical-surgical unit’s standalone valuation, Leerink Partners analyst Michael Cherny said. The company first outlined plans to spin off the unit in May 2025. Since then, it has exited several overseas markets and divested other non-core assets over the past few years.
McKesson Corporation (NYSE:MCK) is a diversified healthcare services company focused on improving patient outcomes. Its US Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter drugs, along with other healthcare-related products across the United States.
3. AbbVie Inc. (NYSE:ABBV)
Number of Hedge Fund Holders: 84
On April 30, Bank of America analyst Tim Anderson upgraded AbbVie Inc. (NYSE:ABBV) to Buy from Neutral. It also lifted the price target on the stock to $234 from $226. The firm believes concerns around competitive erosion in the key immunology segment are “overdone.” It points to strong forward indicators for Skyrizi and says new competitors appear to be “category expanding.” With durable growth expected into the mid-2030s, the firm views AbbVie as offering “one of the best ex-pipeline growth profiles in large cap pharma with room for upside,” the analyst tells investors.
During its Q1 2026 earnings call, AbbVie management tied the quarter’s performance to specific portfolio drivers, along with pipeline progress and business development activity. The company said this included US regulatory submissions for Rinvoq in alopecia areata. It also pointed to Skyrizi’s subcutaneous induction in Crohn’s disease, with an approval decision expected later in the year.
Management also noted the closing of the RemeGen Co., Ltd. agreement, which provides access to a novel PD-1 VEGF bispecific antibody. It further disclosed new US manufacturing investments. The company plans to invest $1.4 billion to build a pharmaceutical manufacturing campus in North Carolina, along with $380 million to construct two new plants in North Chicago.
AbbVie Inc. (NYSE:ABBV) is a global, research-based biopharmaceutical company. It focuses on the development, manufacturing, and commercialization of medicines across immunology, oncology, aesthetics, neuroscience, eye care, and other key areas.
2. The Coca-Cola Company (NYSE:KO)
Number of Hedge Fund Holders: 87
On April 29, TD Cowen raised its price recommendation on The Coca-Cola Company (NYSE:KO) to $90 from $85. It reiterated a Buy rating on the shares. The firm noted the company delivered strong 1Q results and raised EPS due to a lower tax rate. Coca-Cola remains a top pick, supported by its pricing power, steady volume growth, and the resilience of its business model across changing economic, political, and commodity conditions.
During its Q1 2026 earnings call, The Coca-Cola Company President and CFO John Murphy said organic revenue increased 10%, supported by 3% growth in unit case volume. He noted that comparable EPS reached $0.86, up 18% from the prior year, while free cash flow totaled about $1.8 billion. Murphy also said comparable gross margin declined by roughly 30 basis points. Even so, comparable operating margin improved by around 70 basis points, as the company benefited from operating expense efficiencies while continuing to invest in its brands.
Looking ahead, he said the company still expects organic revenue growth of 4% to 5% for 2026. He added that comparable currency-neutral EPS growth, excluding acquisitions and divestitures, is now expected in the range of 6% to 7%.
The Coca-Cola Company (NYSE:KO) is a global beverage company. Its segments include Europe, the Middle East and Africa, Latin America, North America, Asia Pacific, and Bottling Investments. The company sells a broad portfolio of brands across multiple beverage categories worldwide.
1. The Procter & Gamble Company (NYSE:PG)
Number of Hedge Fund Holders: 90
On April 27, TD Cowen raised its price recommendation on The Procter & Gamble Company (NYSE:PG) to $150 from $142. It reiterated a Hold rating on the shares. The firm said volume growth and share trends were strong enough to support the higher target.
During its fiscal Q3 2026 earnings call, the company’s CFO Andre Schulten said the company delivered steady growth in the quarter. He noted that organic sales increased by more than 3% year over year, driven by a 2-point gain in volume and a 1-point contribution from pricing, while mix remained flat. Schulten said growth was broad-based, with all 10 product categories posting organic sales gains.
He added that global aggregate market share improved to roughly in line with the prior year, with momentum building through the quarter. On profitability, he said core EPS was $1.59. He also noted that core gross margin declined by 100 basis points and core operating margin decreased by 80 basis points compared with the prior year. In terms of cash flow, Schulten said adjusted free cash flow productivity reached 82%. He added that the company returned $3.2 billion to shareholders during the quarter, including $2.5 billion in dividends and more than $600 million through share repurchases.
The Procter & Gamble Company (NYSE:PG) provides branded consumer packaged goods to consumers worldwide. Its segments include Beauty, Grooming, Health Care, Fabric & Home Care, and Baby, Feminine & Family Care. The company sells its products in around 180 countries and territories.
While we acknowledge the potential of PG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PG and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best High-Yield Dividend Growth Stocks to Buy Right Now and 10 Innovative Dividend Stocks to Buy Right Now
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
